Friends of Cancer Research is our country's leading voice in advocating for policies and solutions that will get treatments to patients in the safest and quickest way posible.
Since President Obama signed the Breakthrough Therapy designation into law as part of the Food and Drug Administration Safety and Innovation Act, there have already been nine designations announced.
Senator Michael Bennet gave opening remarks at our July briefing on Breakthrough Therapy
Friends of Cancer Research's 2012 Annual Report is now available for download.
Friends Honors Governor Martin O'Malley, Governor Bob McDonnell, and philanthropist Sherry Lansing
National Institutes of Health Director Francis Collins talks about personalized medicine, sequestration, and the future of biomedical research in America on our new forum, Engaging Innovation.
Mydicar - (Celladon)
for reducing hospitalizations for heart failure in NYHA class III or IV chronic heart failure patients
Bexsero - (Novartis)
a vaccine for meningitis B
LDK378 - (Novartis)
for the treatment of non-small cell lung cancer
Dr. William W. Chin, Executive Vice President of Scientific and Regulatory Affairs for PhRMA, talks about his experience with public-private partnerships.
"There isn't a day where I'm not overwhelmed by how many people are dealing with this disease, and that's what drives all of our work at Friends of Cancer Research."
FRIENDS OF CANCER RESEARCH1800 M Street NW Suite 1050 | Washington, DC 20036202.944.6700